Insights on the Incretin Based Drugs Market to 2022 | Industry Statistics, Emerging Demands, Forecast to 2028
The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market’s growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to further propel the diabetes medicines market.
To Request a Sample of our Report on Incretin
Based Drugs Market: https://www.omrglobal.com/request-sample/incretin-based-drugs-market
For instance, in October 2021, Glenmark launched
drug in combination of various incretin based drug types including remogliflozin,
vildagliptin, metformin fixed-dose combination (FDC) at an affordable cost for
adults with type-2 diabetes. Among others, India is the first country to get
access to this FDC drug. Glenmark had received an approval for the drug from
the Drug Controller General of India (DCGI) for manufacturing and marketing
back in September 2021. The new drug launched combines two or more active
incretin based drugs in a single dosage form and can manage most of the
pathophysiology in managing uncontrolled type-2 Diabetes. Further, in April
2019, Glenmark developed Remogliflozin, an oral anti-diabetic medicine that is
deemed helpful in treating individuals with type-2 diabetes mellitus. Thus,
increased product development in emerging countries along with rising healthcare
expenditure will bolster the growth of the market.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Drug Type
·
By Route of Administration
·
By Distribution Channel
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
Rest of the World
Competitive Landscape- including AstraZeneca, Boehringer Ingelheim
International GmbH, Eli Lilly and Co., GlaxoSmithKline plc., Merck & Co.,
and others.
(Get 15% Discount on Buying this Report)
A
full Report of Incretin Based Drugs Market is Available @ https://www.omrglobal.com/industry-reports/incretin-based-drugs-market
Global Incretin Based Drugs Market Report Segment
By Drug Type
·
Glucagon-like Peptide-1 Receptor Agonists
·
Dipeptidyl Peptidase-4 Inhibitor
By Route of Administration
·
Oral
·
Injectable
By Distribution Channel
·
Hospital Pharmacies
·
Retail Pharmacies
·
Online Pharmacies
Global Incretin Based Drugs Market Report Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment